How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The US-China race for artificial intelligence dominance has entered a new phase: using AI to build better AI. Leading AI companies in the United States and China are increasingly focused on deploying ...

Anthropic and OpenAI researchers raised fresh concerns about recursive self-improvement, the process by which AI helps improve the development of models. Both OpenAI and Anthropic have in recent ...

AI is rewriting the world and, at the same time, inventing a whole new language to describe how it’s doing it. Sit in on any product meeting, pitch, or panel these days, and you’ll hear people toss ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...